New York Heart Association classification may be an incomplete predictor of adverse cardiovascular outcomes
1. In this secondary analysis of the PARADIGM-HF trial, the association between the New York Heart Association (NYHA) classification and ...
1. In this secondary analysis of the PARADIGM-HF trial, the association between the New York Heart Association (NYHA) classification and ...
1. LCZ696, a combination of valsartan with a neprilysin inhibitor, significantly reduced the risk of death from cardiovascular causes and ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.